Glenmark Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Glenmark Pharmaceuticals Ltd. on BSE

Search Inside the pdf :

Glenmark Pharmaceuticals Ltd.

22 May 2025, 02:19PM

1431.40

-0.60%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Intimation Of Grant Of Options Under 'Glenmark Pharmaceuticals Limited Employee …

BSE India

Approval for grant of 1,19,318 options pursuant to "Glenmark Pharmaceuticals Limited Employee Stock options Scheme, 2016."

pdf

Glenmark Pharmaceuticals Ltd.

19 May 2025

1431.40

-0.60%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Enclosed please find herewith the details of Earnings Call slated for Monday, May 26, 2025 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.

pdf

Glenmark Pharmaceuticals Ltd.

12 May 2025

1431.40

-0.60%

SAST

Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window

BSE India

The trading window has been closed from March 31, 2025 to May 25, 2025 (both days inclusive) for the purpose of approval of Audited Financial Results for the quarter and year ended March 31, 2025.

pdf

Glenmark Pharmaceuticals Ltd.

12 May 2025

1431.40

-0.60%

Board Meeting

Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Considering And Approving The Standalone And …

BSE India

Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2025 and to consider and recommend dividend, if any, on Equity shares for the year ended March 31, 2025.

pdf

Glenmark Pharmaceuticals Ltd.

09 May 2025

1431.40

-0.60%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Update On Glenmark'S Indore Manufacturing Facility

BSE India

Kindly consider the attached update on Glenmark''s Indore Manufacturing Facility.

pdf

Glenmark Pharmaceuticals Ltd.

05 May 2025

1431.40

-0.60%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Ichnos Glenmark Innovation (IGI) receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/ Refractory Multiple Myeloma

pdf

Glenmark Pharmaceuticals Ltd.

29 Apr 2025

1431.40

-0.60%

Corp. Note

Glenmark Pharmaceuticals Ltd - 532296 - Rumour verification - Regulation 30(11)

BSE India

Clarification/Confirmation on news item appearing in "Media/Publication"

pdf

Glenmark Pharmaceuticals Ltd.

28 Apr 2025

1431.40

-0.60%

Corp. Note

Glenmark Pharmaceuticals Ltd - 532296 - Format of the Annual Disclosure to be made by an …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Glenmark Pharmaceuticals Ltd 2 CIN NO. L24299MH1977PLC019982 3 Report filed for FY 2024-2025 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2023-2024, 2024-2025 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2023-2024, 2024-2025 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Harish KuberDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- V S Mani Designation : -Executive Director and Global Chief Financial Officer Date: 28/04/2025

pdf

Glenmark Pharmaceuticals Ltd.

28 Apr 2025

1431.40

-0.60%

Company Update

Glenmark Pharmaceuticals Ltd - 532296 - Clarification sought from Glenmark Pharmaceuticals Ltd

BSE India

The Exchange has sought clarification from Glenmark Pharmaceuticals Ltd with reference to the media report appearing on https:// www.freepressjournal.in dated April 24, 2025 (Link: https://www.freepressjournal.in/india/cdsco-flags-70-drug-batches-including-telma-40-and-eye-ointments-for-failing-quality-standards-in-march-2025-tests) titled "CDSCO Flags 70 Drug Batches, Including Telma 40 And Eye Ointments, For Failing Quality Standards In March 2025 Tests".The reply is awaited.

Glenmark Pharmaceuticals Ltd.

28 Apr 2025

1431.40

-0.60%

Corp. Note

Glenmark Pharmaceuticals Ltd - 532296 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyGlenmark Pharmaceuticals Ltd 2CIN NO.L24299MH1977PLC019982 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harish Kuber Designation: Company Secretary and Compliance Officer EmailId: harish.kuber@glenmarkpharma.com Name of the Chief Financial Officer: V S Mani Designation: Executive Director and Global Chief Financial Officer EmailId: VS.Mani@glenmarkpharma.com Date: 28/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Glenmark Pharmaceuticals Ltd. worth buying?

560 Votes:

Buy 79.29%

Sell 13.57%

Hold 7.14%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Not Rated SEE REPORTS >

pdf